10 Dec 2024
TAP-funded poster! Treatment of MDS w/primary refractory disease or relapse after frontline therapy remains an unmet medical need. The study shows bexmarilimab plus azacitidine is well tolerated and results in promising efficacy after HMA failure.🩸#ASH24 #LLSTAP @ash_hematology
1
4
868
6 Dec 2024
#ASH2024 is here! Visit the @LLSusa booth (2122) to learn more about #LLSTAP and #venturephilanthropy along with our scientific and patient community efforts and programs!
Thanks to @RgentaTx and Laurie Adami for participating! Visit the LLS booth to see the full video!
1
1
3
360
21 Jun 2024
Congrats to #LLSTAP partner @FaronPharm for completing this important financing round!
21 Jun 2024
Faron’s EUR 30.7 million public offering has ended successfully and was oversubscribed – a warm thank you to everyone who participated.
#bexmarilimab #immunotherapy #biotech #drugDevelopment
2
309
22 Apr 2024
Congrats to Kura Oncology on this important and significant milestone achievement for patients with AML! #LLSTAP
22 Apr 2024
Today we announced the FDA’s decision to grant Breakthrough Therapy Designation for ziftomenib, recognizing its potential as an innovative investigational medicine for patients with relapsed/refractory NPM1-mutant #AML.
Learn more: ir.kuraoncology.com/news-rel…
4
521
6 Oct 2023
Awesome event! Really appreciate #LLSTAP partner @KymeraTx for being a proud supporter of @LLSusa and @LightTheNight - keep up the great work!
6 Oct 2023
Kymerians had fun competing for the title of champion of our annual Ping Pong Tournament! We host this tournament each year to benefit the @LLSusa #LightTheNight campaign. To get involved, check out: lightthenight.org
3
436
18 Sep 2023
Congrats to #LLSTAP partner Kymera on this significant milestone for KT-333! Keep up the great work!
18 Sep 2023
The FDA has granted Fast Track Designation for KT-333, our novel, investigational STAT3 degrader, for the treatment of Relapsed/Refractory Cutaneous T-cell Lymphoma and Relapsed/Refractory Peripheral T-cell Lymphoma. STAT3 has long been considered an undruggable target, and Kymera is committed to pioneering #TPD as we try to advance the standard of care for people with diseases like PTCL and CTCL. Learn more: bit.ly/45WTpfs
1
6
982
30 Aug 2023
Thanks to #LLSTAP partner @kuraoncology for being a proud supporter of @LLSusa and @LightTheNight - keep up the great work!
28 Aug 2023
As we renew support of @LLSusa’s annual Light the Night event, our leadership team will participate in an executive challenge to raise funds and awareness for #bloodcancer research. Follow #TeamKura’s efforts to hit our fundraising goal in the coming months: pages.lls.org/ltn/2023/kurao… #LighttheNight #CancelBloodCancer
6
803
29 Mar 2023
Congrats to #LLSTAP partner @CaribouBio for achieving this important development milestone for CB-010!
29 Mar 2023
The ANTLER trial has advanced into dose expansion! Dose expansion will include second-line patients with large B cell #lymphoma (LBCL), making CB-010 the first allogeneic CAR-T cell therapy to be evaluated in a clinical trial in second-line patients. lnkd.in/gBVecexX
$CRBU
2
439
15 Mar 2023
Ryvu has been named the best company on the Warsaw Stock Exchange for 2022 by @puls_biznesu daily.
We owe our success to our incredibly talented team, as well as our partners and shareholders, who believed in us every step of the way.
Read more (PL): bit.ly/3ZPHSf5
3
305
Did you participate in the latest @LLSusa TAP panel discussion? If not, check the recording to hear how Ryvu and other LLS biotech partners work to bring new therapies to patients.
bit.ly/3wrekqR
#DiscoverForPatients #LLSTAP
5
476
23 Jan 2023
🧵2/3 Elzonris is the 1st FDA approved therapy for children adults with #BPDCN.
1st created with #LLSgrant support to Dr. Arthur Frankel @utsw. #LLSTAP committed $3M in a partnership w/ @Stemline supporting the clinical study leading to approval
bit.ly/3woOBzC
1
1
5
744
18 Jan 2023
Congrats to @BioInvent for becoming the latest #LLSTAP partner! We look forward to working closely together to help advance two clinical therapies for blood cancer patients! Visit our site to learn more about #LLSTAP and all of our portfolio partners: lls.org/tap
17 Jan 2023
BioInvent selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program and receives $3 million strategic equity investment bioinvent.com/en/press/bioin…
1
2
352
17 Jan 2023
Come join #LLSTAP and European TAP partners (@affimed @FaronPharm @RyvuTx and ImCheck) for tomorrow's 12pm ET discussion panel! Hear the latest clinical updates & how each company works with @LLSusa to bring new therapies to patients!
Join us & register @ bit.ly/LLSTAP23
6 Jan 2023
Our Therapy Acceleration Program #LLSTAP is excited to announce the upcoming panel “European Partners Dream Big, Make Bold Progress” highlighting TAP companies @affimed @FaronPharm @RyvuTx and ImCheck on Wed Jan 18 2023 @ 12 pm ET!
Join us & register @ bit.ly/LLSTAP23
1
6
3,415
11 Jan 2023
Impromptu meetings at #JPM2023 are the best. Especially with fellow cancer impact warriors. Hatching next gen invest and innovation approaches with
@LLSUSA
@LLSResearch #LLSTAP
@AmericanCancer BrightEdge #EveryCancerEveryLife #accessinnovation
12
372
6 Jan 2023
Our Therapy Acceleration Program #LLSTAP is excited to announce the upcoming panel “European Partners Dream Big, Make Bold Progress” highlighting TAP companies @affimed @FaronPharm @RyvuTx and ImCheck on Wed Jan 18 2023 @ 12 pm ET!
Join us & register @ bit.ly/LLSTAP23
1
6
3,608
30 Jun 2022
#LLSTAP is proud to partner with @FaronPharm and we look forward to working closely together! To learn more visit lls.org/tap.
29 Jun 2022
#Faron has raised € 5 million in a share placing, welcoming new investor, the @LLSusa Therapy Acceleration Program. Read more on our website: Faron.com/investors
#fundraise #biotech
2
13 Jun 2022
Congrats to @ImcheckThx on their closing! #LLSTAP looks forward to working together to help advance #GammaDelta activating mAbs for blood cancer patients!
1
1 Jun 2022
Congrats to #LLSTAP partner @KymeraTx for receiving Orphan Drug Designation for KT-333 for the treatment of PTCL!
1 Jun 2022
The FDA has granted us Orphan Drug Designation for our investigational treatment KT-333 for the treatment of Peripheral T-cell Lymphoma. STAT3 activation has been shown to be a key modulator of disease in PTCL. Learn more at: bit.ly/3GLe9er
1
6
12 May 2022
Congrats to #LLSTAP partner @CaribouBio for this exciting news for r/r B-NHL patients - 100% ORR & 80% CR. We're looking forward to seeing additional data presented at #EHA2022 in June.
12 May 2022
Excited to announce we are scheduled to share positive initial data for our ANTLER Phase 1 #clinicaltrial of CB-010 at #EHA2022, demonstrating a generally well tolerated safety profile & a 100% ORR & 80% CR in r/r B-NHL patients. Read more: bit.ly/3yrZzGG
1
20 Jan 2022
Join #LLSTAP tomorrow Jan 21 @ 12pm ET to learn more about the companies @LLSusa supports who are leading the development of next-generation cell therapies for blood cancers! Register @ bit.ly/LLSTAP22
AbintusBio @CaribouBio @CarismaTher @NexImmune
14 Jan 2022
#LLSTAP is excited to announce our upcoming panel Expanding the Possible with Next-Generation Cell Therapies highlighting TAP partners Abintus Bio, @CaribouBio @CarismaTher and @NexImmune on Friday Jan 21 2022 @ 12 pm ET!
Please join us and register @ bit.ly/LLSTAP22
